Highlights on gastroesophageal tumors: the comeback of FLOT

• DOI: 10.1007/s12254-024-01014-3
• Publication Date: 2025-01-14T00:06:16Z
• Authors: Aysegul Ilhan-Mutlu
• Keywords: Neoadjuvant Therapy; Chemoradiotherapy

Summary This article aims to summarize the highlights of two largest global congresses 2024 with respect gastroesophageal tumors. The triplet chemotherapy combination known as FLOT (5-fluorouracil, leucovorin, oxaliplatin, docetaxel), used perioperative chemotherapy, was demonstrated improve overall and disease-free survival in resectable cancer patients some time ago. Despite being standard for this patient population, many questions different scenarios remain open: Is also efficacious esophageal or junction adenocarcinoma when compared neoadjuvant chemoradiotherapy? a feasible option oligometastatic patients, thereby contributing “neoadjuvant” treatment before palliative resection? Can efficacy be strengthened by applying additional radiation adenocarcinoma? really necessary adjuvant setting all can guided based on pathological response rates? These were answered extent ESOPEC RENAISSANCE trials at American Society Clinical Oncology (ASCO) meeting TOPGEAR SPACE-FLOT European Medical (ESMO) meeting. Many other FLOT-related studies well metastatic are yet come.